BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. (BCTXF) priced its initial public offering on Feb 25, 2021 at $4.25 per share, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $23.9M. ThinkEquity was lead-left underwriter. Sichenzia Ross Ference Carmel and Bennett Jones advised the company and Clark Wilson advised the underwriters.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company developing cancer treatments, with a focus on advanced breast cancer. Its lead candidate, Bria-IMT, a whole cell targeted immunotherapy, is in a Phase I/IIa trial combined with immune checkpoint inhibitors under a collaboration with Incyte.

Status

IPO

Ticker

BCTXF

Exchange

Nasdaq Capital Market

Priced

Feb 25, 2021

IPO price

$4.25

Market cap at IPO price

$23.9M

First filed

Oct 22, 2019

Underwriters

ThinkEquity

Company counsel

Sichenzia Ross Ference Carmel and Bennett Jones

Underwriters' counsel

Clark Wilson

Sector

Biotech & pharma

Country / state

British Columbia, Canada

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.